Tag: Cadila Healthcare
Zydus gets go ahead for phase-2 clinical trial of its novel...
The company will soon begin the Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS), a rare life-long auto-inflammatory condition in Australia
Pharma industry reiterates its commitment to US$ 130 billon by 2030
Innovation, R&D, partnership & policy support to be key growth drivers as echoed at Global Innovation Summit-2021 organized by Indian Pharmaceutical Alliance
Zydus seeks DCGI’s EUA for world’s first Plasmid DNA based COVID-19...
The company has presented interim results from Phase III clinical trials in over 28,000 volunteers in a study carried out in more than 50 clinical sites spread across the country and during the peak of second wave of COVID-19.......................
Bayer & Zydus extend their joint venture by 3 years
Bayer Zydus Pharma will continue to operate in therapies including cardiology, diabetes, women’s health, ophthalmology and oncology, with new products in the pipeline.......................
Zydus launches Ujvira, a breakthrough biosimilar for breast cancer treatment
The world’s first biosimilar Antibody Drug Conjugate of Trastuzumab Emtansine will be priced at nearly 80% less than the currently available option in the market.......................
Zydus Cadila to divest its India focused animal health business
The deal is to sell one of the two business undertakings of ZAHL, called Animal Healthcare Established Markets Undertaking for a lump sum consideration of Rs. 2921 crores.....................
Zydus’s COVID-19 drug ‘Virafin’ gets DCGI nod
91.15% of patients treated with PegIFN were RT PCR negative by day 7. A single dose of the antiviral Virafin administered subcutaneously early on shows significant clinical and virological improvement in moderate COVID-19 adult patients.......................
Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b...
Promising interim results from Phase III clinical trials with Pegylated Interferon alpha-2b in COVID-19 show higher clinical improvement.........................
DigiHealth to invest in developing a world-class supply chain & distribution...
The investment has been made with a view to develop a world-class pharmaceutical supply chain & distribution IT ecosystem and support the government’s National Digital Health Mission.............................